Zyprexa Makers Investigated for Marketing Practices
Zyprexa is a medication approved to treat people with schizophrenia and severe bipolar disorder and has been known to cause serious side effects. Eli Lilly, makers of Zyprexa has been under investigation for its marketing practices since 2004. In late 2000, Lilly began a marketing campaign called Viva Zyprexa and told its sales representatives to suggest that doctors prescribe Zyprexa to older patients with symptoms of dementia. Internal documents and company emails have shown that Eli Lilly was planning to encourage doctors to prescribe Zyprexa for people with age-related dementia and mild bipolar disorder. Articles published in the New York Times in December 2006 describe Lilly’s multiyear effort to play down Zyprexa’s side effects and to promote the drug for other conditions. This practice is known as off-label marketing. Currently, federal prosecutors are discussing settling a civil and criminal investigation into the company’s marketing of the antipsychotic drug that could cost them $1 billion to be paid to federal and state governments. Lilly has already paid $1.2 billion to settle 30,000 lawsuits from people who claim that Zyprexa caused them to contract diabetes and other diseases. Zyprexa can cause severe weight gain and has been linked to diabetes by the American Diabetes Association. The Justice Department lawyers in Washington pressed for a grand jury investigation to examine whether Lilly should be charged criminally for its promotional activities.













